Is KMDA or COYA more profitable?

Kamada has a net margin of 11.21% compared to Coya Therapeutics' net margin of -266.10%. Kamada's return on equity of 7.73% beat Coya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kamada 11.21% 7.73% 5.41% Coya Therapeutics -266.10% -55.86% -48.86%

Do analysts recommend CGC or COYA?

Coya Therapeutics has a consensus target price of $15.33, indicating a potential upside of 223.49%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Coya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Does the media favor CGC or COYA?

In the previous week, Canopy Growth and Canopy Growth both had 7 articles in the media. Canopy Growth's average media sentiment score of 1.46 beat Coya Therapeutics' score of 0.48 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 3 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NGNE or COYA?

In the previous week, Coya Therapeutics had 3 more articles in the media than Neurogene. MarketBeat recorded 7 mentions for Coya Therapeutics and 4 mentions for Neurogene. Neurogene's average media sentiment score of 1.11 beat Coya Therapeutics' score of 0.48 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to COYA or STTK?

In the previous week, Shattuck Labs had 13 more articles in the media than Coya Therapeutics. MarketBeat recorded 20 mentions for Shattuck Labs and 7 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.48 beat Shattuck Labs' score of 0.44 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Shattuck Labs 4 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer ADCT or COYA?

In the previous week, Coya Therapeutics had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 7 mentions for Coya Therapeutics and 5 mentions for ADC Therapeutics. Coya Therapeutics' average media sentiment score of 0.48 beat ADC Therapeutics' score of -0.49 indicating that Coya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Coya Therapeutics (COYA) Competitors

$4.74 +0.10 (+2.16%)

Closing price 04:00 PM Eastern

Extended Trading

$4.66 -0.09 (-1.79%)

As of 05:10 PM Eastern

Compare

COYA vs. KMDA, CGC, NGNE, STTK, and ADCT

Should you buy Coya Therapeutics stock or one of its competitors? MarketBeat compares Coya Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Coya Therapeutics include Kamada (KMDA), Canopy Growth (CGC), Neurogene (NGNE), Shattuck Labs (STTK), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry.

How does Coya Therapeutics compare to Kamada?

Kamada (NASDAQ:KMDA) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

20.4% of Kamada shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 36.1% of Kamada shares are owned by insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Kamada currently has a consensus price target of $12.00, indicating a potential upside of 61.29%. Coya Therapeutics has a consensus price target of $15.33, indicating a potential upside of 223.49%. Given Coya Therapeutics' higher probable upside, analysts plainly believe Coya Therapeutics is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Kamada has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

Kamada has higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$181.68M	2.35	$20.20M	$0.35	21.26
Coya Therapeutics	$7.94M	14.01	-$21.23M	-$1.15	N/A

Kamada has a net margin of 11.21% compared to Coya Therapeutics' net margin of -266.10%. Kamada's return on equity of 7.73% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

In the previous week, Coya Therapeutics had 6 more articles in the media than Kamada. MarketBeat recorded 7 mentions for Coya Therapeutics and 1 mentions for Kamada. Kamada's average media sentiment score of 1.87 beat Coya Therapeutics' score of 0.48 indicating that Kamada is being referred to more favorably in the media.

Company	Overall Sentiment
Kamada	Very Positive
Coya Therapeutics	Neutral

Summary

Kamada beats Coya Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Coya Therapeutics compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Coya Therapeutics has lower revenue, but higher earnings than Canopy Growth. Coya Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$225.65M	1.79	-$429.86M	-$1.30	N/A
Coya Therapeutics	$7.94M	14.01	-$21.23M	-$1.15	N/A

Coya Therapeutics has a consensus target price of $15.33, indicating a potential upside of 223.49%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Canopy Growth has a net margin of -94.39% compared to Coya Therapeutics' net margin of -266.10%. Canopy Growth's return on equity of -46.85% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-94.39%	-46.85%	-28.95%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

In the previous week, Canopy Growth and Canopy Growth both had 7 articles in the media. Canopy Growth's average media sentiment score of 1.46 beat Coya Therapeutics' score of 0.48 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	3 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Canopy Growth has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

3.3% of Canopy Growth shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Coya Therapeutics beats Canopy Growth on 8 of the 15 factors compared between the two stocks.

How does Coya Therapeutics compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Coya Therapeutics has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	N/A	N/A	-$90.35M	-$4.55	N/A
Coya Therapeutics	$7.94M	14.01	-$21.23M	-$1.15	N/A

In the previous week, Coya Therapeutics had 3 more articles in the media than Neurogene. MarketBeat recorded 7 mentions for Coya Therapeutics and 4 mentions for Neurogene. Neurogene's average media sentiment score of 1.11 beat Coya Therapeutics' score of 0.48 indicating that Neurogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neurogene has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Neurogene's return on equity of -37.88% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 11.7% of Neurogene shares are owned by insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Neurogene has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

Neurogene presently has a consensus price target of $79.86, suggesting a potential upside of 174.42%. Coya Therapeutics has a consensus price target of $15.33, suggesting a potential upside of 223.49%. Given Coya Therapeutics' higher probable upside, analysts plainly believe Coya Therapeutics is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Neurogene beats Coya Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Coya Therapeutics compare to Shattuck Labs?

Coya Therapeutics (NASDAQ:COYA) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Coya Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

In the previous week, Shattuck Labs had 13 more articles in the media than Coya Therapeutics. MarketBeat recorded 20 mentions for Shattuck Labs and 7 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.48 beat Shattuck Labs' score of 0.44 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Shattuck Labs	4 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Shattuck Labs has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Shattuck Labs	N/A	-60.73%	-55.75%

Coya Therapeutics has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.94M	14.01	-$21.23M	-$1.15	N/A
Shattuck Labs	$1M	378.80	-$48.81M	-$0.63	N/A

Coya Therapeutics currently has a consensus price target of $15.33, indicating a potential upside of 223.49%. Shattuck Labs has a consensus price target of $11.00, indicating a potential upside of 122.67%. Given Coya Therapeutics' higher possible upside, equities analysts clearly believe Coya Therapeutics is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by company insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Shattuck Labs beats Coya Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Coya Therapeutics compare to ADC Therapeutics?

ADC Therapeutics (NYSE:ADCT) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Coya Therapeutics has lower revenue, but higher earnings than ADC Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.65	-$142.62M	-$1.05	N/A
Coya Therapeutics	$7.94M	14.01	-$21.23M	-$1.15	N/A

In the previous week, Coya Therapeutics had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 7 mentions for Coya Therapeutics and 5 mentions for ADC Therapeutics. Coya Therapeutics' average media sentiment score of 0.48 beat ADC Therapeutics' score of -0.49 indicating that Coya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADC Therapeutics has a net margin of -173.02% compared to Coya Therapeutics' net margin of -266.10%. ADC Therapeutics' return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

ADC Therapeutics presently has a consensus price target of $6.25, suggesting a potential upside of 492.98%. Coya Therapeutics has a consensus price target of $15.33, suggesting a potential upside of 223.49%. Given ADC Therapeutics' higher probable upside, equities analysts plainly believe ADC Therapeutics is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 5.4% of ADC Therapeutics shares are owned by insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ADC Therapeutics has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Summary

ADC Therapeutics beats Coya Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Coya Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COYA vs. The Competition

Export

Metric	Coya Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$111.19M	$3.37B	$6.50B	$11.98B
Dividend Yield	N/A	2.32%	2.67%	5.57%
P/E Ratio	-4.12	19.65	23.85	24.45
Price / Sales	14.01	312.48	534.74	122.24
Price / Cash	N/A	120.36	43.20	54.62
Price / Book	2.30	8.32	10.66	6.80
Net Income	-$21.23M	$23.89M	$3.56B	$337.76M
7 Day Performance	7.24%	0.94%	0.05%	2.08%
1 Month Performance	10.49%	-1.16%	0.35%	3.16%
1 Year Performance	-11.73%	41.52%	22.72%	27.79%

Coya Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COYA Coya Therapeutics	2.8487 of 5 stars	$4.74 +2.2%	$15.33 +223.5%	-17.6%	$111.19M	$7.94M	N/A	6	Analyst Forecast
KMDA Kamada	4.9888 of 5 stars	$7.51 -2.5%	$12.00 +59.8%	+7.1%	$442.79M	$180.46M	21.46	360	Positive News
CGC Canopy Growth	1.9368 of 5 stars	$1.06 -1.9%	N/A	-35.7%	$436.45M	$225.65M	N/A	3,150	Positive News Upcoming Earnings
NGNE Neurogene	3.5274 of 5 stars	$26.14 -5.1%	$74.17 +183.7%	+38.6%	$435.19M	N/A	N/A	90	Positive News Analyst Forecast
STTK Shattuck Labs	4.4553 of 5 stars	$4.87 -13.8%	$13.00 +166.9%	+287.0%	$433.24M	$1M	N/A	100	Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COYA) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coya Therapeutics (COYA) Competitors

COYA vs. KMDA, CGC, NGNE, STTK, and ADCT

How does Coya Therapeutics compare to Kamada?

Summary

How does Coya Therapeutics compare to Canopy Growth?

Summary

How does Coya Therapeutics compare to Neurogene?

Summary

How does Coya Therapeutics compare to Shattuck Labs?

Summary

How does Coya Therapeutics compare to ADC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA vs. The Competition

Coya Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coya Therapeutics (COYA) Competitors

COYA vs. KMDA, CGC, NGNE, STTK, and ADCT

How does Coya Therapeutics compare to Kamada?

Do insiders and institutionals believe in KMDA or COYA?

Do analysts recommend KMDA or COYA?

Which has more risk & volatility, KMDA or COYA?

Which has higher earnings & valuation, KMDA or COYA?

Is KMDA or COYA more profitable?

Does the media favor KMDA or COYA?

Summary

How does Coya Therapeutics compare to Canopy Growth?

Which has preferable earnings and valuation, CGC or COYA?

Do analysts recommend CGC or COYA?

Is CGC or COYA more profitable?

Does the media favor CGC or COYA?

Which has more volatility & risk, CGC or COYA?

Do insiders & institutionals believe in CGC or COYA?

Summary

How does Coya Therapeutics compare to Neurogene?

Which has preferable valuation & earnings, NGNE or COYA?

Does the media prefer NGNE or COYA?

Is NGNE or COYA more profitable?

Do insiders and institutionals hold more shares of NGNE or COYA?

Which has more risk & volatility, NGNE or COYA?

Do analysts recommend NGNE or COYA?

Summary

How does Coya Therapeutics compare to Shattuck Labs?

Which has more volatility & risk, COYA or STTK?

Does the media refer more to COYA or STTK?

Is COYA or STTK more profitable?

Which has preferable valuation & earnings, COYA or STTK?

Do analysts rate COYA or STTK?

Do insiders and institutionals have more ownership in COYA or STTK?

Summary

How does Coya Therapeutics compare to ADC Therapeutics?

Which has preferable earnings & valuation, ADCT or COYA?

Does the media prefer ADCT or COYA?

Is ADCT or COYA more profitable?

Do analysts rate ADCT or COYA?

Do insiders & institutionals hold more shares of ADCT or COYA?

Which has more volatility and risk, ADCT or COYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA vs. The Competition

Coya Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools